Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling

BACKGROUND: Selective estrogen receptor modulators, such as tamoxifen, play a pivotal role in the treatment of luminal-type breast cancer. However, in clinical applications, nearly half of breast cancer patients are insensitive to tamoxifen, a small number of whom have early recurrence or disease pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Mu, Xin, Huang, Ou, Xie, Zuoquan, Jiang, Min, Geng, Meiyu, Shen, Kunwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753350/
https://www.ncbi.nlm.nih.gov/pubmed/23991038
http://dx.doi.org/10.1371/journal.pone.0072053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753350/
https://www.ncbi.nlm.nih.gov/pubmed/23991038
http://dx.doi.org/10.1371/journal.pone.0072053

Ejemplares similares